Idenix Pharmaceuticals Edges Higher – Sees Slow Crawl Higher Despite Morning Downgrade

Biotechnology, Healthcare, Idenix Pharmaceuticals
Biotechnology, Healthcare, Idenix Pharmaceuticals

Idenix Pharmaceuticals (IDIX) is posting modest gains in today’s regular session, slowly crawling higher after sitting just above flat earlier in the day. The stock has struggled Friday in the wake of a UBS downgrade to Neutral from Buy. Further gains will be fighting against the downgrade as well as the stock’s current levels, holding just below its 52-week high of $24.21.

Idenix Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of human viral diseases in the United States and France.


Please enter your comment!
Please enter your name here